DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial
December 16, 2021 08:59 ET | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523
December 01, 2021 07:02 ET | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Doses First Participants in Altitude Trial
November 22, 2021 07:02 ET | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Oxygen Independence and Improved Health Security for Barbados
November 13, 2021 12:38 ET | World Hope International
Bridgetown, Barbados, Nov. 13, 2021 (GLOBE NEWSWIRE) -- In the face of ongoing COVID-19 cases across the island, the Government of Barbados is partnering with the US Southern Command, World Hope...
xebec square logo.png
Xebec Announces Q3 2021 Financial Results
November 11, 2021 07:00 ET | Xebec Adsorption
MONTREAL, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Xebec Adsorption Inc. (TSX: XBC) ("Xebec"), a global provider of clean energy solutions, announced today its 2021 third quarter results, with the...
xebec square logo.png
Xebec annonce ses résultats financiers pour le troisième trimestre de 2021
November 11, 2021 07:00 ET | Xebec Adsorption
MONTRÉAL, 11 nov. 2021 (GLOBE NEWSWIRE) -- Xebec Adsorption Inc. (TSX : XBC) (« Xebec »), fournisseur mondial de solutions d’énergie propre, a annoncé aujourd’hui ses résultats du troisième...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
November 10, 2021 07:02 ET | Diffusion Pharmaceuticals Inc.
Announces Intent to Develop TSC to Treat Hypoxic TumorsAltitude Trial Expected to Commence in November 2021ILD-DLCO Trial Expected to Commence in Late December 2021 CHARLOTTESVILLE, Va., Nov. ...
Nikkiso Logo - blue_CMYK_transp_bar_ends - cropped - REDONE.jpg
Nikkiso Cosmodyne Commissions TGNO-1000 Developed for Float Glass Applications
September 15, 2021 02:00 ET | Cryogenic Industries
TEMECULA, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (Group), a subsidiary of Nikkiso Co., Ltd (Japan), is pleased to announce...
Diffusion Pharmaceuticals Issues Letter to Shareholders
September 09, 2021 07:32 ET | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division
August 30, 2021 07:32 ET | Diffusion Pharmaceuticals Inc.
Phase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND  Fourth FDA Division to Clear TSC IND   CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Diffusion...